Oruka Therapeutics, Inc. ORKA
Updated: 17 Jun 2026
No signal published yet
We already track Oruka Therapeutics and collect the news. No signal is published yet — follow the company free and we will email you when that changes, or run a quick check now.
Email when we publish a signal or something material happens · Sunday weekly brief
No card · No time limit on free tier · Upgrade when you need more
Temporary check — not Firelda's published signal.
General analysis — not personal advice.
Want to follow Oruka Therapeutics, Inc.? Create a free account — 3 companies, change history, weekly brief, and email when the picture changes.
Follow Oruka Therapeutics free Follow freeEmail when we publish a signal or something material happens · Sunday weekly brief
No card · No time limit on free tier · Upgrade when you need more
Recent News
In May 2026, the company reported positive interim Phase 2a data for ORKA-001, demonstrating significant skin clearance in patients with moderate-to-severe plaque psoriasis. During April 2026, Oruka completed an upsized $700 million public offering to fund the advancement of its clinical pipeline. The company also announced a global collaboration with Halozyme to utilize Hypercon technology for ORKA-001.
What Firelda Watch includes for Oruka Therapeutics, Inc.
Add the company to your watchlist and get all of this automatically.
- Free: 3 companies on your watchlist
- Change history and monitoring for every company you follow
- Sunday weekly brief — a short weekly roundup
- Watch/Ultra: same-day email when something material happens
Want to see what a finished analysis looks like?
View a sample analysis
Want to follow Oruka Therapeutics, Inc.? Create a free account — 3 companies, change history, weekly brief, and email when the picture changes.
Follow Oruka Therapeutics free Follow freeEmail when we publish a signal or something material happens · Sunday weekly brief
No card · No time limit on free tier · Upgrade when you need more